Neurology and Neurosurgery

Episodes 1-16 of 64

• 

  RestartResume

   Pinpointing CIDP: Diagnosis Challenges and Misdiagnosis/Delayed Diagnosis of CIDP

  RestartResume

   Pinpointing CIDP: Diagnosis Challenges and Misdiagnosis/Delayed Diagnosis of CIDP

  MinuteCE®

   Pinpointing CIDP: Diagnosis Challenges and Misdiagnosis/Delayed Diagnosis of CIDP

  1.00 program credit

  • 

    

    Jeffrey Allen, MD

  • 

    

    Nicholas J. Silvestri, MD, FAAN

  1.00 program credit

• 

  RestartResume

  Novel Mechanisms of Action: FcRn Inhibitors

  RestartResume

  Novel Mechanisms of Action: FcRn Inhibitors

  MinuteCE®

  Novel Mechanisms of Action: FcRn Inhibitors

  1.00 program credit

  • 

    

    Jeffrey Allen, MD

  • 

    

    Nicholas J. Silvestri, MD, FAAN

  1.00 program credit

• 

  RestartResume

  CIDP Monitoring Challenges: Suboptimal Responses in CIDP Treatment

  RestartResume

  CIDP Monitoring Challenges: Suboptimal Responses in CIDP Treatment

  MinuteCE®

  CIDP Monitoring Challenges: Suboptimal Responses in CIDP Treatment

  1.00 program credit

  • 

    

    Jeffrey Allen, MD

  • 

    

    Nicholas J. Silvestri, MD, FAAN

  1.00 program credit

• 

  RestartResume

  Why Early and Accurate CIDP Diagnosis Matters: The Role of Standardized Tools

  RestartResume

  Why Early and Accurate CIDP Diagnosis Matters: The Role of Standardized Tools

  MinuteCE®

  Why Early and Accurate CIDP Diagnosis Matters: The Role of Standardized Tools

  1.00 program credit

  • 

    

    Jeffrey Allen, MD

  • 

    

    Nicholas J. Silvestri, MD, FAAN

  1.00 program credit

• 

  RestartResume

  Decoding CIDP: Exploring Common and Atypical Variants

  RestartResume

  Decoding CIDP: Exploring Common and Atypical Variants

  MinuteCE®

  Decoding CIDP: Exploring Common and Atypical Variants

  1.00 program credit

  • 

    

    Jeffrey Allen, MD

  • 

    

    Nicholas J. Silvestri, MD, FAAN

  1.00 program credit

• 

  RestartResume

  Navigating CIDP Treatments: IVIg and Steroid Advantages and Limitations

  RestartResume

  Navigating CIDP Treatments: IVIg and Steroid Advantages and Limitations

  MinuteCE®

  Navigating CIDP Treatments: IVIg and Steroid Advantages and Limitations

  1.00 program credit

  • 

    

    Jeffrey Allen, MD

  • 

    

    Nicholas J. Silvestri, MD, FAAN

  1.00 program credit

• 

  RestartResume

  Autoantibodies in CIDP: Prevalence and Diagnostic Implications

  RestartResume

  Autoantibodies in CIDP: Prevalence and Diagnostic Implications

  MinuteCE®

  Autoantibodies in CIDP: Prevalence and Diagnostic Implications

  1.00 program credit

  • 

    

    Jeffrey Allen, MD

  • 

    

    Nicholas J. Silvestri, MD, FAAN

  1.00 program credit

• 

  MinuteCE®

  Incorporating FcRn Inhibitors Into Clinical Practice in Chronic Inflammatory Demyelinating Polyneuropathy

  1.00 credit 10 episodes

  • 

    

    Jeffrey Allen, MD

  • 

    

    Nicholas J. Silvestri, MD, FAAN

  1.00 credit 10 episodes

• 

  RestartResume

  Implementing CIDP Clinical Guidelines: Optimizing Therapy

  RestartResume

  Implementing CIDP Clinical Guidelines: Optimizing Therapy

  MinuteCE®

  Implementing CIDP Clinical Guidelines: Optimizing Therapy

  1.00 program credit

  • 

    

    Nicholas J. Silvestri, MD, FAAN

  • 

    

    Jeffrey Allen, MD

  1.00 program credit

• 

  RestartResume

  Comprehensive CIDP Care: The Role of Multidisciplinary Teams and Patient-Reported Outcomes

  RestartResume

  Comprehensive CIDP Care: The Role of Multidisciplinary Teams and Patient-Reported Outcomes

  MinuteCE®

  Comprehensive CIDP Care: The Role of Multidisciplinary Teams and Patient-Reported Outcomes

  1.00 program credit

  • 

    

    Jeffrey Allen, MD

  • 

    

    Nicholas J. Silvestri, MD, FAAN

  1.00 program credit

• 

  RestartResume

  Clinical Benefits of FcRn Inhibitors: Innovations in CIDP Management and Treatment

  RestartResume

  Clinical Benefits of FcRn Inhibitors: Innovations in CIDP Management and Treatment

  MinuteCE®

  Clinical Benefits of FcRn Inhibitors: Innovations in CIDP Management and Treatment

  1.00 program credit

  • 

    

    Nicholas J. Silvestri, MD, FAAN

  • 

    

    Jeffrey Allen, MD

  1.00 program credit

• 

  RestartResume

  Patient-Centric Approaches to Optimizing Outcomes in AAD: Case Review

  RestartResume

  Patient-Centric Approaches to Optimizing Outcomes in AAD: Case Review

  CME/CE

  Patient-Centric Approaches to Optimizing Outcomes in AAD: Case Review

  0.25 credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  0.25 credits

• 

  RestartResume

  Safety, Efficacy, and Black Box Warnings: Challenges Associated With Off-Label Treatments of AAD

  RestartResume

  Safety, Efficacy, and Black Box Warnings: Challenges Associated With Off-Label Treatments of AAD

  MinuteCE®

  Safety, Efficacy, and Black Box Warnings: Challenges Associated With Off-Label Treatments of AAD

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  RestartResume

  Caregiver Screening Tools for Agitation in Alzheimer’s Disease

  RestartResume

  Caregiver Screening Tools for Agitation in Alzheimer’s Disease

  MinuteCE®

  Caregiver Screening Tools for Agitation in Alzheimer’s Disease

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  RestartResume

  Proactive Screening: Essential Tools for Diagnosing AAD Quickly

  RestartResume

  Proactive Screening: Essential Tools for Diagnosing AAD Quickly

  MinuteCE®

  Proactive Screening: Essential Tools for Diagnosing AAD Quickly

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  MinuteCE®

  Optimizing Outcomes in AAD in Community PCP and LTC Clinics

  1.25 credits 11 episodes

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 credits 11 episodes